The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients.
Publication/Presentation Date
11-30-2007
Abstract
Liver biopsy is currently the gold standard for determining the stage of liver fibrosis. There are risks associated with liver biopsy; therefore, surrogate markers to predict the severity of disease would be useful. We studied 50 patients with HIV/hepatitis C co-infection who had liver biopsies and determined that no patient with an aspartate aminotransferase/platelet ratio index (APRI) of 0.6 or less had stage F3 or F4 disease. The APRI is useful for excluding advanced disease in this patient population.
Volume
21
Issue
18
First Page
2541
Last Page
2543
ISSN
1473-5571
Published In/Presented At
Shastry, L., Wilson, T., Lascher, S., & Nord, J. A. (2007). The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients. AIDS (London, England), 21(18), 2541–2543. https://doi.org/10.1097/QAD.0b013e3282f1fe59
Disciplines
Medicine and Health Sciences
PubMedID
18025895
Department(s)
Department of Medicine
Document Type
Article